Repligen: Riding the Wave of Renewed Confidence and Stabilized Demand

Conestoga Capital's Q4 2025 Market Overview: A Year of Volatility and Key Leadership

Conestoga Capital Advisors provided an update on market performance in their fourth-quarter 2025 investor letter, reflecting on a year of robust returns for US equities. Despite double-digit gains across major indices, the underlying market conditions were marked by extreme volatility and shifts in leadership. The firm's Small Cap Strategy recorded a net-of-fees return of -1.89% in Q4 2025, falling short of the Russell 2000 Growth Index's 1.22% return. This period saw continued, albeit slower, momentum in "low quality" stocks.

Repligen Corporation's Performance Snapshot: A Deep Dive into a Bioprocessing Leader

Repligen Corporation (NASDAQ: RGEN), a prominent life science company specializing in bioprocessing technologies and systems, was singled out by Conestoga Capital Advisors. The company's shares experienced a one-month return of -17.76% and a 52-week decline of 15.10%. As of February 18, 2026, RGEN closed at $138.11 per share, boasting a market capitalization of $7.774 billion. These figures paint a picture of a company facing recent headwinds but poised for a turnaround.

Conestoga's Perspective on Repligen's Resurgence: Overcoming Challenges and Eyeing Future Growth

In their Q4 2025 letter, Conestoga Capital Advisors specifically commented on Repligen Corporation, noting its role as a supplier of essential bioprocessing equipment and consumables for biologic drug manufacturing. The firm observed a strong rebound in RGEN shares, attributing this to clear signs that industry destocking had reached its lowest point and order patterns were becoming more consistent. This improved clarity regarding growth in 2026, coupled with effective cost management, led to higher expectations for operating leverage. Consequently, investors re-evaluated the stock, shifting their focus beyond short-term fluctuations to appreciate RGEN's superior consumables portfolio, solid market standing, and the long-term growth potential within the biologics market.

Hedge Fund Interest and Alternative Investment Considerations for Savvy Investors

While Repligen Corporation (NASDAQ:RGEN) is not currently among the top 30 most popular stocks favored by hedge funds, data from the end of the third quarter showed 53 hedge fund portfolios holding RGEN, an increase from 49 in the preceding quarter. This indicates a growing, albeit not mainstream, interest in the company. For investors seeking alternative high-growth opportunities, especially in the rapidly evolving AI sector, there are other undervalued AI stocks that could offer substantial upside potential, particularly those positioned to benefit from shifting trade policies and onshoring trends. These alternatives might present a more compelling risk-reward profile.